These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

501 related items for PubMed ID: 19092365

  • 41. Vasopressin and Vasopressin Antagonists in Heart Failure.
    Vishram-Nielsen JK, Gustafsson F.
    Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
    [Abstract] [Full Text] [Related]

  • 42. Therapeutic role of vasopressin receptor antagonism in patients with liver cirrhosis.
    Ferguson JW, Therapondos G, Newby DE, Hayes PC.
    Clin Sci (Lond); 2003 Jul; 105(1):1-8. PubMed ID: 12639215
    [Abstract] [Full Text] [Related]

  • 43. Mechanisms, risks, and new treatment options for hyponatremia.
    Ghali JK.
    Cardiology; 2008 Jul; 111(3):147-57. PubMed ID: 18434717
    [Abstract] [Full Text] [Related]

  • 44. Hyponatremia in heart failure.
    Chatterjee K.
    J Intensive Care Med; 2009 Jul; 24(6):347-51. PubMed ID: 19850560
    [Abstract] [Full Text] [Related]

  • 45. Role of vasopressin antagonists.
    Torres VE.
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1212-8. PubMed ID: 18434616
    [Abstract] [Full Text] [Related]

  • 46. Therapeutic potential of vasopressin-receptor antagonists in heart failure.
    Izumi Y, Miura K, Iwao H.
    J Pharmacol Sci; 2014 Jul; 124(1):1-6. PubMed ID: 24401675
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Vasopressin antagonists: role in the management of hyponatremia.
    Yeates KE, Morton AR.
    Am J Nephrol; 2006 Jul; 26(4):348-55. PubMed ID: 16837788
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Role of tolvaptan in acute decompensated heart failure.
    Ho JE, Teerlink JR.
    Expert Rev Cardiovasc Ther; 2008 Jun; 6(5):601-8. PubMed ID: 18510477
    [Abstract] [Full Text] [Related]

  • 52. Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study.
    Goldsmith SR, Elkayam U, Haught WH, Barve A, He W.
    J Card Fail; 2008 Oct; 14(8):641-7. PubMed ID: 18926434
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Vasopressin receptor antagonists in heart failure.
    Hobbs RE, Tang WH.
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127
    [Abstract] [Full Text] [Related]

  • 55. The science behind hyponatremia and its clinical manifestations.
    Schrier RW.
    Pharmacotherapy; 2011 May; 31(5 Suppl):9S-17S. PubMed ID: 21923421
    [Abstract] [Full Text] [Related]

  • 56. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management.
    Ginès P, Guevara M.
    Hepatology; 2008 Sep; 48(3):1002-10. PubMed ID: 18671303
    [Abstract] [Full Text] [Related]

  • 57. AVP receptor antagonists as aquaretics: review and assessment of clinical data.
    Verbalis JG.
    Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150
    [Abstract] [Full Text] [Related]

  • 58. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.
    Finley JJ, Konstam MA, Udelson JE.
    Circulation; 2008 Jul 22; 118(4):410-21. PubMed ID: 18645067
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Hyponatremia: current treatment strategies and the role of vasopressin antagonists.
    Cawley MJ.
    Ann Pharmacother; 2007 May 22; 41(5):840-50. PubMed ID: 17405824
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.